• Users Online: 183
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most cited articles *

 
 
  Archives   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
REVIEWS
A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase
Peter Y. M. Woo, Yi Li, Anna H. Y. Chan, Stephanie C. P. Ng, Herbert H. F. Loong, Danny T. M. Chan, George K. C. Wong, Wai-Sang Poon
April-June 2019, 2(2):68-82
DOI:10.4103/glioma.glioma_3_19  
  15 8,871 1,075
Molecular mechanisms involved in angiogenesis and potential target of antiangiogenesis in human glioblastomas
Yang Xu, Fan-En Yuan, Qian-Xue Chen, Bao-Hui Liu
March-April 2018, 1(2):35-42
DOI:10.4103/glioma.glioma_10_17  
  10 6,015 681
Pediatric high-grade glioma: A heterogeneous group of neoplasms with different molecular drivers
Francesca Gianno, Manila Antonelli, Elisabetta Ferretti, Maura Massimino, Antonietta Arcella, Felice Giangaspero
July-August 2018, 1(4):117-124
DOI:10.4103/glioma.glioma_27_18  
  6 10,207 1,195
Nanoparticles drug-delivery systems and antiangiogenic approaches in the treatment of gliomas
Maria Caffo, Salvatore Massimo Cardali, Elena Fazzari, Valeria Barresi, Gerardo Caruso
November-December 2018, 1(6):183-188
DOI:10.4103/glioma.glioma_43_18  
  6 4,679 479
ORIGINAL ARTICLES
BRAF mutation marks out specific subgroups of glioma
Aden Ka-Yin Chan, Riki Rui-Qi Zhang, Abudumijiti Aibaidula, Zhi Feng Shi, Hong Chen, Ying Mao, Ho Keung Ng
September-October 2018, 1(5):168-174
DOI:10.4103/glioma.glioma_33_18  
  5 5,523 565
Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
Pingde Zhang, Ning Li, Karrie Mei Yee Kiang, Zhiyuan Zhu, Gloria Wai Man Leung, Stephen Yin Cheng, Gilberto Ka Kit Leung
September-October 2018, 1(5):175-181
DOI:10.4103/glioma.glioma_37_18  
  4 4,122 396
Increased expression of von Willebrand factor gene is associated with poorer survival in primary lower grade glioma
Steven Lehrer, Peter H Rheinstein, Kenneth E Rosenzweig
July-August 2018, 1(4):132-135
DOI:10.4103/glioma.glioma_17_18  
  4 3,704 396
YKL-40 in high-grade glioma: Prognostic value of protein versus mRNA expression
Yu-Hang Zhao, Zhi-Yong Pan, Ze-Fen Wang, Chao Ma, Hong Weng, Zhi-Qiang Li
May-June 2018, 1(3):104-110
DOI:10.4103/glioma.glioma_16_18  
  4 4,031 369
Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report
Chengcheng Guo, Qunying Yang, Jiawei Li, Shaoxiong Wu, Meiling Deng, Xiaojing Du, Ke Sai, Xiaobing Jiang, Zhenghe Chen, Ji Zhang, Fuhua Lin, Jian Wang, Yinsheng Chen, Chao Ke, Xiangheng Zhang, Xue Ju, Yonggao Mou, Jeffrey Bacha, Anne Steino, Sarath Kanekal, Claire Kwan, Gregory Johnson, Richard Schwartz, John Langlands, Dennis Brown, Zhong-ping Chen
October-December 2019, 2(4):167-173
DOI:10.4103/glioma.glioma_25_19  
  4 4,780 324
REVIEWS
Histological approach to neuronal and mixed neuronal-glial tumors of the central nervous system
Char Loo Tan, Roger E McLendon
May-June 2018, 1(3):89-96
DOI:10.4103/glioma.glioma_24_18  
  4 7,975 942
ORIGINAL ARTICLES
Reprogramming glioma cell cultures with retinoic acid: Additional arguments for reappraising the potential of retinoic acid in the context of personalized glioma therapy
Matthieu Dreyfus, Michèle El-Atifi, Magali Court, Marie Bidart, Charles Coutton, Céline Leclech, Bruno Ballester, Emmanuel Garcion, Ali Bouamrani, François Berger, Didier Wion
March-April 2018, 1(2):66-78
DOI:10.4103/glioma.glioma_3_18  
  3 4,813 450
Vasculogenic mimicry persists during glioblastoma xenograft growth
Cong Li, Yin-Sheng Chen, Qing-Ping Zhang, Jian-Liang Chen, Jing Wang, Fu-Rong Chen, Ho-Keung N G, Zhong-Ping Chen
January-February 2018, 1(1):16-21
DOI:10.4103/glioma.glioma_4_17  
  3 4,752 437
REVIEWS
Myeloid-derived suppressor cells and nonresolving inflammatory cells in glioma microenvironment: molecular mechanisms and therapeutic strategies
Xiao-Yan Ji, Jia-Wei Ma, Jun Dong
January-February 2018, 1(1):2-8
DOI:10.4103/glioma.glioma_2_17  
  3 4,276 451
EDITORIAL
The new WHO molecular criteria for adult glioblastoma – Are we a step too far?
Ho-Keung Ng, Queenie Hoi-Wing Wong, Emma Munan Liu, Kay Ka-Wai Li
October-December 2021, 4(4):65-67
DOI:10.4103/glioma.glioma_19_21  
  2 2,167 202
ORIGINAL ARTICLES
Patterns of computed tomographic findings in patients from Maiduguri, Nigeria, diagnosed with a brain tumor
Alhaji Modu Ali, Maryam Abdullahi Buji, Ahmed Abubakar
July-September 2019, 2(3):153-156
DOI:10.4103/glioma.glioma_11_19  
  2 3,151 229
O-6-methylguanine-DNA methyltransferase promoter methylation can change in glioblastoma recurrence due to intratumor heterogeneity
Valeria Barresi, Maria Caffo, Giuseppa De Luca, Giuseppe Giuffrè
November-December 2018, 1(6):208-213
DOI:10.4103/glioma.glioma_38_18  
  2 3,413 318
Evidence of calcium-activated potassium channel subunit alpha-1 as a key promoter of glioma growth and tumorigenicity
Divya Khaitan, Nagendra Ningaraj
January-March 2019, 2(1):46-54
DOI:10.4103/glioma.glioma_44_18  
  2 3,308 236
REVIEW
Repurposing drugs for the treatment of glioma
Chengming Xu, Yaodong Zhao, Congyan Wu, Lei Li
October-December 2019, 2(4):159-164
DOI:10.4103/glioma.glioma_26_19  
  2 2,637 252
REVIEWS
Role of natural killer cells in isocitrate dehydrogenase 1/2 mutant glioma pathogenesis and emerging therapies
Xiaoran Zhang, Aleksandra Safonova, Aparna Rao, Nduka Amankulor
July-September 2019, 2(3):133-138
DOI:10.4103/glioma.glioma_10_19  
  2 4,361 396
Current management of glioma in Pakistan
Umm E Hani Abdullah, Altaf Ali Laghari, Muhammad Usman Khalid, Huzaifa Bin Rashid, Adnan Abdul Jabbar, Fatima Mubarak, Asim Hafiz, Shahzad Shamim, Syed Ather Enam
July-September 2019, 2(3):139-144
DOI:10.4103/glioma.glioma_15_19  
  2 5,051 366
Combination of oncolytic viruses and immune checkpoint inhibitors in glioblastoma
Kunal Desai, Anne Hubben, Manmeet Ahluwalia
January-March 2019, 2(1):7-19
DOI:10.4103/glioma.glioma_5_19  
  2 6,617 503
Gamma-delta T cells in glioblastoma immunotherapy
Sadhak Sengupta
January-March 2019, 2(1):30-36
DOI:10.4103/glioma.glioma_48_18  
  2 7,666 756
Ongoing evolution of response assessment in glioma: Where do we stand?
Li Yi, Haolang Ming, Shengping Yu, Bingcheng Ren, Xuejun Yang
May-June 2018, 1(3):97-103
DOI:10.4103/glioma.glioma_13_18  
  2 5,081 503
The advances in targeted therapy and immunotherapy for glioblastoma: Basic research and clinical trials
Mei Wang, Xiaochun Jiang, Fubing Wu, Haojun Xu, Zihong Lin, Bin Qi, Hongping Xia
May-June 2018, 1(3):79-88
DOI:10.4103/glioma.glioma_10_18  
  2 6,665 741
CASE REPORT
Diffuse midline glioma, H3-K27M mutant: Awareness leads to identification
Sadhana Tiwari, Ishita Pant, Sujata Chaturvedi, Gurbachan Singh
January-March 2019, 2(1):55-59
DOI:10.4103/glioma.glioma_1_19  
  1 4,311 297
* Source: CrossRef